TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21570352
Drug: Anthracycline regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline regimen (FEC): six cycles of intravenous fluorouracil 500 mg/m², epirubicin 100 mg/m², and cyclophosphamide 500 mg/m² or fluorouracil 600 mg/m², epirubicin 75 mg/m², cyclophosphamide 900 mg/m².
Study: 8811519
Drug: Calorie-dense milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie-dense milk (5.0 kJ/ml with a protein-energy ratio of 11.0)
Study: 1393487
Drug: Haemoccult screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoccult screening test for rectal cancers
Study: 27249005
Drug: 300 U
Normalized name: lactase 3300 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 U BoNT‐A injection into the detrusor every six months
Study: 25061252
Drug: Oral Pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Pressure Therapy (OPT) device
Study: 22777041
Drug: ST-246 400
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-246 400 mg
Study: 22777041
Drug: ST-246 600
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-246 600 mg
Study: 11821457
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg orally once daily for 6 weeks
Study: 11821457
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg orally once daily for 6 weeks
Study: 1911657
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) ointment and placebo drops (AP)
Study: 1911657
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment with steroid drops (PS)
Study: 1911657
Drug: Acyclovir ointment
Normalized name: Acyclovir Ointment
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir ointment with steroid drops (AS)
Study: 9039254
Drug: Automatic NCPAP
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic NCPAP titration (Horizon, DeVilbiss)
Study: 9039254
Drug: Manual NCPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual NCPAP titration
Study: 7960016
Drug: High cardiorespiratory
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cardiorespiratory fitness (VO2peak 46.6 +/- 6.5 mL.kg-1.min-1)
Study: 7960016
Drug: Moderate cardiorespiratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate cardiorespiratory fitness (VO2peak 35.9 +/- 1.9 mL.kg-1.min-1)
Study: 3236323
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily nitrendipine (20 mg)
Study: 3236323
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily nitrendipine (20 mg)
Study: 25742730
Drug: Saquinavir/ritonavir 500/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir/ritonavir 500/100 mg BID on days 1-7 and 1000/100 mg BID on days 8-14
Study: 20463104
Drug: HIV-1 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 DNA vaccine (intradermally or intramuscularly) with GM-CSF adjuvant, boosted with modified vaccinia virus Ankara (HIV-MVA) at 9 months
Study: 10534036
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of intravenous methyl prednisolone administered prehospital to asthma patients (11 patients in year 2)
Study: 10534036
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients who did not receive prehospital steroids)
Study: 6353878
Drug: 0.075 mg
Normalized name: mestranol 0.075 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg clonidine at 8 a.m. and 0.15 mg at 10 p.m.
Study: 22985564
Drug: Nucleoside analogue
Normalized name: Nucleoside analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside analogue (NA) treatment
Study: 24863037
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel
Study: 10501818
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg per day
Study: 23722352
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of 1% oestrone cream applied once daily for 24 weeks
Study: 22704121
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block (2.5 ml of the same mixture) plus intrarectal local anesthesia (lidocaine 1.5%-nifedipine 0.3% cream)
Study: 17296646
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (n = 109)
Study: 11318078
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol solution twice daily
Study: 9776370
Drug: Psychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications and counseling (index group)
Study: 3395668
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release pseudoephedrine suspension (CR)
Study: 3395668
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release reference syrup (IR-Sudafed)
Study: 28668671
Drug: Deutetrabenazine 36
Normalized name: deutetrabenazine 36 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine 36 mg/day
Study: 28668671
Drug: Deutetrabenazine 24
Normalized name: deutetrabenazine 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine 24 mg/day
Study: 15446505
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) measurements in patients with ischemia
Study: 15446505
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) measurements in healthy controls
Study: 9382207
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (lmw-heparin) at 1.5-5 IE/kg body weight per hour
Study: 8103145
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion (50 micrograms intravenous bolus plus 50 micrograms per h intravenous infusion for 48 h)
Study: 27030533
Drug: DHA-rich fish-oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish-oil capsules (800 mg DHA/d)
Study: 27030533
Drug: Vegetable-oil capsules
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable-oil capsules (control group)
Study: 25519880
Drug: Preventive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive chemotherapy with praziquantel (exact dosage and duration not specified)
Study: 18230353
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg x 3/day, group A)
Study: 18230353
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg/day, group G)
Study: 15722313
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 20-25 mg of triamcinolone acetonide
Study: 29512336
Drug: Temporary anchorage
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary anchorage devices (TADs) used in orthodontic treatment, including 50 (3M ESPE), 56 (Bone screw), and 74 (Morelli) TADs, with lengths of 6, 8, and 10 mm and diameters of 1.5, 1.6, and 1.8 mm, and force levels set at 50, 100, 150, 200, and 250 g.
Study: 15076203
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg without active pretreatment (placebo)
Study: 15076203
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg after 5 days' treatment with amiloride 5 mg twice daily
Study: 15076203
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no active drugs)
Study: 12536532
Drug: BZX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZX treatment
Study: 9286940
Drug: Fradafiban (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fradafiban (1 to 15 mg continuously infused over 30 minutes)
Study: 9286940
Drug: Lefradafiban (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefradafiban (single oral doses of 50 mg, 100 mg, and 150 mg)
Study: 9286940
Drug: Lefradafiban (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefradafiban (oral TID for 7 days)
Study: 28682929
Drug: Rasagiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (1 mg)
Study: 28682929
Drug: Safinamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide (50 mg or 100 mg)
Study: 24309336
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a dose of 2 to 2.5 mg/kg as induction dose and sedation maintained with 5 to 10 mg/min.
Study: 20451972
Drug: No scalpel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No scalpel vasectomy with distal vasal flushing (30 mL of sterile water)
Study: 19030713
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg, orally in a single dose, 1 hour before bedtime for 21 consecutive days
Study: 8657519
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg rhSOD
Study: 1724525
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of L + C vs L + GG
Study: 16393213
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment (group 1)
Study: 10459447
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of urinary follicle‐stimulating hormone (FSH, Fostimon 75, A.M.S.A., Italy)
Study: 10459447
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of urinary follicle‐stimulating hormone (FSH, Metrodin 75 HP, Serono, Italy)
Study: 2719903
Drug: Buccal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal morphine
Study: 28758717
Drug: EPA+DHA therapy
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA therapy
Study: 22084332
Drug: Dabigatran, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran, 150 mg or 110 mg twice daily
Study: 15505965
Drug: Dual-route model
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-route model treatment
Study: 15505965
Drug: Single-route model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-route model treatment
Study: 3982903
Drug: Aminophylline plus
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline plus doxapram therapy
Study: 29140864
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL 0.5% bupivacaine with 1:200,000 epinephrine (Group A)
Study: 29140864
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of 1% lidocaine with 1:100,000 epinephrine (Group B)
Study: 24946636
Drug: Embedding therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embedding therapy on back‐shu points and front‐mu points and needle‐pricking therapy on Sifeng (EX‐UE 10)
Study: 17500623
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR treatment
Study: 12114418
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (400 mg/day given p.o.)
Study: 8026259
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg every other day (group C)
Study: 2918132
Drug: Chlorhexidine varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine varnish (second treatment)
Study: 26817306
Drug: Oral sertraline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sertraline hydrochloride at 50 mg qd for 12 weeks
Study: 15132126
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (single dose)
Study: 9789694
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (control group).
Study: 145654
Drug: Administration by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by investigator
Study: 145654
Drug: Self-administration by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration by patients
Study: 21699587
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL of oral supplement and dietary advice
Study: 8110568
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 40 ml with morphine 5 mg (group BM5)
Study: 2761061
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (1.2 g)
Study: 779054
Drug: Indoramin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (mean dose: 158 ± 9 mg per day)
Study: 779054
Drug: Methyldopa (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (mean dose: 1540 ± 90 mg per day)
Study: 25908703
Drug: CPMHA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPMHA with lidocaine (BEL‐L)
Study: 25908703
Drug: Control: CPMHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: CPMHA with lidocaine (BEL‐L)
Study: 21226678
Drug: Zolpidem (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (5 mg)
Study: 20178218
Drug: 16% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16% carbamide peroxide bleaching agent (Pola Night) for 2 hours a day for 3 weeks
Study: 19088953
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bleaching treatment)
Study: 11689755
Drug: Triple sulfonamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple sulfonamide vaginal cream
Study: 7696452
Drug: Budesonide retention
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide retention enema (2.3 mg/115 mL)
Study: 14985932
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zolpidem
Study: 22767144
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m² plus Irinotecan 250 mg/m² (Day 1)
Study: 22767144
Drug: Docetaxel 85
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 85 mg/m² (Day 1) followed by 5-fluorouracil 750 mg/m² per day (Days 1-5)
Study: 894973
Drug: Modified pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modified pilocarpine solution
Study: 894973
Drug: Pure pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure pilocarpine solution
Study: 17181400
Drug: Action Schools!
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Schools! BC (AS! BC) intervention including a daily jumping program (Bounce at the Bell) plus 15 minutes/day of classroom physical activity.
Study: 6294517
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous cyclophosphamide plus ACTH
Study: 6294517
Drug: Plasma exchange,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange, low-dose oral cyclophosphamide, and ACTH
Study: 31496674
Drug: Indacaterol (IND)
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol (IND) 150 μg q.d.
Study: 31496674
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 μg q.d.
Study: 29945934
Drug: Newer-generation ultrathin
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer-generation ultrathin strut drug-eluting stents (strut thickness <70 µm)
Study: 29945934
Drug: Thicker strut
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thicker strut second-generation drug-eluting stents
Study: 1105692
Drug: Intra-amniotic PGF2alpha
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic PGF2alpha 40 mg
Study: 16529667
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 microg every 4 hours (to a maximum of four doses)
Study: 10480263
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied three times per week for up to 16 weeks
Study: 8583605
Drug: 3-drug mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-drug mixture (17.64 mg/ml papaverine, 0.58 mg/ml phentolamine, 5.8 micrograms/ml prostaglandin E1)
Study: 1918458
Drug: Tretinoin emollient
Normalized name: Tretinoin Emollient Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin emollient 0.05% cream
Study: 3950112
Drug: Vehicle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle therapy
Study: 26946148
Drug: Cumulative duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative duration of triple-low state (low MAP <65 mmHg, low BIS <45, low Ce <1.5 μg ml-1 of propofol anesthesia)
Study: 21167689
Drug: Cognitive enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive enhancement therapy (CET)
Study: 21629190
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14 capsules)
Study: 19443419
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (2 mg kg(‐1) h(‐1) during surgery and 1 mg kg(‐1) min(‐1) for the first 24 postoperative hours)
Study: 11316241
Drug: i.v. Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. Fe alone (same dose as Group A)
Study: 9396542
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (2 to 8 sessions)
Study: 7895957
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (experimental group, n = 16)
Study: 7895957
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (control group, n = 5)
Study: 27821210
Drug: Olanzapine 15
Normalized name: olanzapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 15 mg once daily
Study: 27821210
Drug: Asenapine 2.5
Normalized name: asenapine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 2.5 mg bid
Study: 27821210
Drug: Asenapine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (both doses)
Study: 22656044
Drug: Non-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-guided treatment (clopidogrel non-responders did not undergo any change in treatment)
Study: 22656044
Drug: Non-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-guided treatment
Study: 15249618
Drug: Women initiating
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women initiating hormones at older ages
Study: 16413249
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole
Study: 7770708
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole
Study: 3099028
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin (FOM) otic solution
Study: 30260372
Drug: iPad administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iPad administration of the Pattern Comparison Processing Speed Test
Study: 30260372
Drug: iPad administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iPad administration of the Dimensional Change Card Sort Test
Study: 30260372
Drug: iPad administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iPad administration of the List Sorting Working Memory Test
Study: 15010697
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg plus titrated dose of yohimbine (F/Y)
Study: 15010697
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg plus placebo (F/P)
Study: 11379254
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic therapy, free to receive treatment or exercises)
Study: 788907
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine (DHE) 2 mg three times daily for 14 days
Study: 18931211
Drug: 0.1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL/kg of 1% lidocaine with 1:200,000 epinephrine (0.5 mug/kg of epinephrine) IV
Study: 12670779
Drug: Formoterol pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol pre-treatment + formoterol 18 microg
Study: 11105736
Drug: Stepwise initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Stepwise initiation (a sequence of 1 week each on placebo; olanzapine, 5 mg q.d.; and olanzapine, 10 mg q.d.)